Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Edaravone
Drug ID BADD_D02508
Description Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.
Indications and Usage Indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of ALS.
Marketing Status approved; investigational
ATC Code N07XX14
DrugBank ID DB12243
KEGG ID D01552
MeSH ID D000077553
PubChem ID 4021
TTD Drug ID D06DLI
NDC Product Code 53296-0120; 70510-2171; 53069-1070; 72643-034; 70510-2322; 70510-2191; 16436-0120; 69037-0060; 70510-2321; 64552-4098; 14501-0100; 71796-017; 73435-008
UNII S798V6YJRP
Synonyms Edaravone | Norantipyrine | Norphenazone | Edarabone | 1-Phenyl-3-methyl-5-pyrazolone | 1 Phenyl 3 methyl 5 pyrazolone | 3-Methyl-1-phenyl-2-pyrazolin-5-one | 3 Methyl 1 phenyl 2 pyrazolin 5 one | MCI 186 | MCI-186 | MCI186 | Radicava | Phenylmethylpyrazolone
Chemical Information
Molecular Formula C10H10N2O
CAS Registry Number 89-25-8; 19735-89-8
SMILES CC1=NN(C(=O)C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute hepatic failure09.01.03.0010.000538%Not Available
Altered state of consciousness17.02.04.001; 19.07.01.0030.000538%Not Available
Amyotrophic lateral sclerosis17.05.05.0040.005114%Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000538%
Aphasia19.21.01.001; 17.02.03.0010.006568%
Asthenia08.01.01.0010.015074%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.004038%Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.0030.001077%Not Available
Chills15.05.03.016; 08.01.09.0010.003284%
Coma17.02.09.0010.000538%Not Available
Condition aggravated08.01.03.0040.015720%Not Available
Death08.04.01.0010.037953%
Discomfort08.01.08.0030.001830%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000808%
Drug ineffective08.06.01.0060.039299%Not Available
Dysarthria19.19.03.001; 17.02.08.0010.000538%
Dysphagia07.01.06.0030.002100%
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.0040.001184%
Dyspnoea02.11.05.003; 22.02.01.0040.006837%
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.001184%
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.0020.011251%
Haemorrhage intracranial24.07.04.003; 17.08.01.0080.000538%
Haemothorax12.01.18.005; 24.07.01.008; 22.05.02.0010.000808%
Hepatic function abnormal09.01.02.0010.000538%Not Available
Muscular weakness15.05.06.001; 17.05.03.0050.006945%
Oedema14.05.06.010; 08.01.07.0060.001184%Not Available
Pancreatic carcinoma16.13.10.001; 07.21.09.0020.000538%Not Available
Pericardial haemorrhage24.07.01.013; 02.06.01.0030.000538%Not Available
Pleural effusion22.05.02.0020.000808%
Pulmonary embolism24.01.06.001; 22.06.02.0010.000808%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages